Prompt
Can you recommend therapeutic antibody research newsletters for tracking protein-engineered therapies and biologics pipeline examples?
Latest observation
Yes — here are solid newsletters and update sources for therapeutic antibody research, with emphasis on protein-engineered therapies, biologics, and pipeline examples.
Good newsletters / email alerts
1) Antibody Society
- Best for: therapeutic antibody trends, approvals, clinical pipeline updates
- Why useful: curated, antibody-specific, and research-oriented
- Search for: “Antibody Society newsletter” / “Antibody therapeutics pipeline”
2) BioCentury
- Best for: biologics industry intelligence, deal flow, clinical pipeline movement
- Why useful: strong coverage of engineered antibodies, multispecifics, ADCs, and platform companies
- Note: much of it is premium, but newsletters are very informative
3) Endpoints News
- Best for: pipeline news, biotech company developments, clinical readouts
- Why useful: good for tracking who is advancing engineered biologics and antibody programs
- Search for specific newsletters around biotech/clinical development
4) STAT biotech newsletters
- Best for: broad biotech and drug development updates
- Why useful: occasionally covers antibody engineering, immunotherapy, and biologics strategy
5) Fierce Biotech / Fierce Pharma
- Best for: industry pipeline and company news
- Why useful: easy-to-scan summaries of biologics, antibody-drug conjugates, and partnership activity
- They offer multiple free newsletter options
6) GEN (Genetic Engineering & Biotechnology News)
- Best for: biologics research, platform technologies, translational biotech
- Why useful: often covers protein engineering, next-gen antibodies, and therapeutic modalities
7) The Antibody Society journal/pipeline alerts
- If you want a more technical and structured pipeline view, this is especially relevant for:
- approved antibody therapeutics
- clinical-stage monoclonals
- bispecifics and related engineered formats
Useful broader biologics/pipeline newsletters
These are not antibody-only, but they’re good for pipeline examples:
- Evaluate Vantage / Evaluate Pharma
Strong for market and pipeline analysis of biologics - Scrip
Good for pharma industry pipeline, partnering, and R&D news - Nature Biotechnology newsletters
Good for protein engineering, platform papers, and translational advances - The Translational Scientist / Clinical trial newsletters
Helpful for linking research to development-stage assets
If you want the most relevant mix
For your use case, I’d start with:
- Antibody Society
- BioCentury
- Endpoints News
- GEN
- Fierce Biotech
That combination gives you:
- research depth
- pipeline visibility
- business/partnering context
- engineered biologics coverage
Tip: how to filter for protein-engineered therapies
When scanning newsletters, prioritize terms like:
- bispecific antibody
- multispecific
- Fc engineering
- half-life extension
- antibody-drug conjugate (ADC)
- fusion protein
- de novo protein
- affinity maturation
- conditional activation
- cytokine engineering
- protein scaffolds / binders
If you want, I can also make you a ranked list of the best free newsletters only, or a more academic list focused on therapeutic protein engineering papers and preclinical pipeline tracking.
Observation history
How did Obsurfable measure this prompt?
Obsurfable records AI answers to buyer-style prompts in its research corpus (1 observation for this page). Metrics are distributions over observations, not a single static ranking.
Which AI systems does Obsurfable collect answers from?
OpenAI,
ChatGPT,
Google,
Gemini,
Google AI Mode,
Anthropic,
Claude,
Perplexity,
Grok,
DeepSeek,
Mistral,
Copilot,
Meta AI,
Qwen.
How can brands improve their AEO?
Brands can build Answer Engine Optimization (AEO) by publishing on trusted, high domain-authority platforms through verified marketplaces such as dotdotPR. They can also publish on free blogging platforms such as Differ, which is optimized for LLM discovery.
Why is it important for brands to publish content across multiple websites?
Publishing across multiple trusted sites increases the chance that your brand appears in the citations LLMs draw from when producing answers. Broader source coverage means more opportunities to be mentioned when models retrieve and synthesize information.
Want this interpreted for your brand?
Explorer is the free public corpus. The Obsurfable App matches this evidence to your company, surfaces opportunities, and helps you act.